Stoke Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Stoke Therapeutics, Inc. (NASDAQ: STOK) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 4:30 p.m. ET. The conference will feature a live audio webcast available on the company's investor relations website, along with a replay accessible for 30 days post-event. Stoke focuses on developing RNA-based medicines to address severe diseases by upregulating protein expression, with its lead compound STK-001 currently in clinical testing for Dravet syndrome.

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 4:30 p.m. ET.

A live audio webcast of the presentation will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/. A replay of the webcast will be available for 30 days following the presentation.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using the Company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The Company’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. The Company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the Company’s belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the Company on Twitter at @StokeTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005252/en/

Stoke Investor:

Eric Rojas

Vice President, Investor Relations

IR@stoketherapeutics.com

617-312-2754

Source: Stoke Therapeutics, Inc.

FAQ

When is Stoke Therapeutics presenting at the J.P. Morgan Healthcare Conference?

Stoke Therapeutics will present at the J.P. Morgan Healthcare Conference on January 10, 2022, at 4:30 p.m. ET.

Where can I listen to Stoke Therapeutics' presentation?

The live audio webcast of Stoke Therapeutics' presentation will be available on the company's investor relations website.

What is STK-001 being tested for?

STK-001 is being tested for the treatment of Dravet syndrome, a severe genetic epilepsy.

What approach does Stoke Therapeutics use for its medicines?

Stoke Therapeutics uses a proprietary approach called TANGO to develop RNA-based medicines that upregulate protein expression.

What diseases is Stoke Therapeutics targeting?

Stoke Therapeutics is targeting haploinsufficient diseases, including Dravet syndrome and autosomal dominant optic atrophy (ADOA).